The evolution and understanding of skeletal complication endpoints in clinical trials of tumors with metastasis to the bone
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Date
2019Journal
Critical Reviews in Oncology/HematologyPublisher
Elsevier Ireland LtdType
article
Metadata
Show full item recordAbstract
Bone metastases are a frequent complication of solid tumors, leading to significant skeletal sequelae that negatively impact quality of life and survival. Prevention and management of skeletal-related complications are critical treatment goals in oncology. Endpoints used in clinical trials to evaluate skeletal-related complications have evolved. In contrast to single measures of bone health, contemporary clinical trial endpoints reflect composite measures of skeletal-related complications, and increasingly also survival. In addition, key symptomatic components, which are more reflective of quality of life and the patient experience, are being incorporated. Given the evolution and resulting diversity of the endpoints being used in pivotal trials, it is becoming increasingly relevant to clarify the utility and the potential clinical impact of these measures not only within the context of trials but also in the real-world setting. Here, we describe the development and evolution of skeletal endpoints used in trials, and discuss their clinical relevance. Copyright 2019 The AuthorsSponsors
Part of AH's time was supported by a Merit Review Award (I01 BX000545), Medical Research Service, Department of Veterans Affairs .Identifier to cite or link to this item
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85066431295&doi=10.1016%2fj.critrevonc.2019.04.020&partnerID=40&md5=2bc6747d3a7777c35fa9ca5f552b0b52; http://hdl.handle.net/10713/10236ae974a485f413a2113503eed53cd6c53
10.1016/j.critrevonc.2019.04.020
Scopus Count
Collections
Related articles
- Bisphosphonates for breast cancer.
- Authors: Pavlakis N, Stockler M
- Issue date: 2002
- Denosumab for the prevention of skeletal-related events in patients with bone metastasis from solid tumor.
- Authors: Iranikhah M, Wilborn TW, Wensel TM, Ferrell JB
- Issue date: 2012 Mar
- Bisphosphonates: clinical experience.
- Authors: Coleman RE
- Issue date: 2004
- Metastatic cancer in solid tumors and clinical outcome: skeletal-related events.
- Authors: Rove KO, Crawford ED
- Issue date: 2009 Dec
- Efficacy and safety of zoledronic acid in the treatment of bone metastases associated with lung cancer and other solid tumors.
- Authors: Rosen LS
- Issue date: 2002 Dec